Second Sight Medical Products Inc (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that provide functional vision to blind patients, announced that Matthew J. Pfeffer, Corporate Vice President and Chief Financial Officer of MannKind Corporation, has been appointed to its Board of Directors effective immediately.Mr. Pfeffer qualifies as a financial expert under SEC regulations, and will serve as the Chair of the Committee.
“We are excited to welcome Matthew Pfeffer to the Board and to draw on his expertise as a seasoned life sciences executive and leader in our industry as we work to build the market for the Argus® II Retinal Prosthesis, advance our product pipeline, and build shareholder value,” said Dr. Robert Greenberg, President and CEO of Second Sight.
“Matthew Pfeffer will bring the same thoughtful financial leadership to Second Sight that he has delivered as Chief Financial Officer of MannKind. I am confident that he will make a meaningful and immediate contribution to our distinguished Board of Directors,” added Alfred E. Mann, Chairman of the Board of Directors of Second Sight and Executive Chairman of the Board of Directors of MannKind Corporation.
Since 2008, Mr. Pfeffer has been Corporate Vice President and Chief Financial Officer of MannKind Corporation. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance andAdministration of VaxGen, Inc., with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. where during his nine year tenure he served as Director of Finance before being named CFO in 1998. Mr. Pfeffer previously served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit, and Manager of Financial Reporting. Mr. Pfeffer is a Certified Public Accountant and began his career at Price Waterhouse. (Original Source)
Shares of Second Sight Medical Products closed yesterday at $13.71 . EYES has a 1-year high of $24.02 and a 1-year low of $8.05. The stock’s 50-day moving average is $12.71 and its 200-day moving average is $12.60.
Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa.